Артериальная гипертензия

Расширенный поиск

Ожирение, симпатическая гиперактивность и артериальная гипертензия -есть ли связь?

Полный текст:


Все известные компоненты метаболического синдрома так или иначе ассоциированы с гиперактивностью симпатической нервной системы. Симпатическая гиперактивность принимает участие в патогенезе артериальной гипертензии, ассоциированной с ожирением. Эта связь осуществляется при участии лептина, инсулина, свободных жирных кислот, а также синдрома обструктивного апноэ сна. Применение препаратов, уменьшающих активность симпатической нервной системы, у данной категории пациентов следует считать патогенетически обоснованным.

Об авторе

А. О. Конради
ФГУ НИИ кардиологии им. В.А. Алмазова Росздрава

Список литературы

1. Hugget R.J., Bums J., Mackintosh A.F., Мату D. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 2004; 44:847-852.

2. Montani J.P., Antic V., Yang Z., Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Obesity 2002; 26 (Suppl. 2):S28-S38.

3. Triosi R.L., Weiss S.T., Parker D.R. et al. Relation of obesity and diet to sympathetic nervous system activity. Hypertension 1991; 14:669-677.

4. Sowers J.R., Nyby M., Stern N. et al. Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension 1982; 4:686-691.

5. Tuck M. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992; 19:167-177.

6. Young J.B., MacDonald I.A. Sympathoadrenal activity in human obesity: heterogeneity if finding since 1980. Int J Obesity 1992; 16:959-967.

7. Vas M., Jennings G., Turmer A. et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997; 96:3423-3429.

8. Rumantir M.S., Vas M., Jennings G. et al. Neural mechanisms in human obesity-related hypertension. J Нуpertens 1999; 17:1125-1133.

9. Grassi G., Colombo M., Seravalle G. et al. Dissociation between muscle and skin sympathetic nerve activity in hypertension, obesity, and heart failure. Hypertension 1998; 31:896-899.

10. Scherrer U., Randin D., Tappy D.R. et al. Body fat and sympathetic nerve activity in healthy subjects. Circulation 1994; 82:2634-2640.

11. Grassi G. Debating sympathetic overactivity as a hallmark of human obesity: a pro position J Hypertension 1999; 17:1059-1060.

12. Somers V.K. Debating sympathetic overactivity as a hallmark of human obesity: an opposite position. J Hypertension 1999; 17:1061-1064.

13. Grassi G., Servalle G., Dell'Oro R. et al. Participation of the hypothlamus-hypophysys axis in the sympathetic activation of human obesity. Hypertension 2001; 38:1316-1320.

14. Grassi G., Dell’oro R., Facchini A. Et al. Effect of central and peripheral fat distribution on sympathetic and baroreflex function in obese normotensives.J Hypertens 2004; 22:2363-2369.

15. Alvarez G.E., Beske S.D., Ballard T.P., Davy K.P. Sympathetic neural activation in visceral obesity. Circulation 2002;106:2533-2536.

16. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. QJ Med 1986; 236:1081-1090.

17. Landsberg L., Young J.B. Fasting, feeding and regulation of the sympathetic nervous system. N EngJ Med 1978; 298:1295-1301.

18. Verwaerde P., Senard J.M., Galiener M. et al. Changes in shortterm variability of blood pressure and heart rate during the development of obesity-associated hypertension in high-fat fed dogs. J Hypertension 1999; 17:1135-1143.

19. O’Dea K., Esler M., Leinard P. et al. Noradrenaline turnover during under- and overeating in normal weight subjects. Metabolism 1982; 31:896-899.

20. Ravussin E., Bogardus C. A brief overview of human energy metabolism and its relationship to essential obesity. Am J Clin Nutr 1992; 55(suppl):242S-245S

21. Poehlmann E.T., Gardner A.W., Goran M.I., et al. Sympathetic nervous system activity, body fatness, and body distribution in younger and males. J Appl Physiol 1995; 78: 802-806.

22. Paolisso G., Manzella D., Ferrana N., et al. Glucose ingestion affects cardiac ANS in health subjects with different amounts of body fat. Am J Physiol 1997; 273:E417-E478.

23. Di Bona G.F. Sympathetic neural control of the kidney in hypertension. Hypertension 1992; 19:1-28-1-35.

24. Haynes W.G., Sivitz W.I., Morgan D.A. et al. Sympathetic and cardiac actions of leptin. Hypertension 1997; 30:619-623.

25. Weisner G., Vaz M., Collier G. et al. Leptin is released from the brain: influence of adiposity and gender. J Clin Endocrinol Metabol 1999; 84:2270-2274.

26. Tanida M., Iwashita S., Ootsuka Y. et al, Leptin injection into white adipose tissue elevates renal sympathetic nerve activity dose-dependentlu through the afferent nerves pathway in rats. Neusosci Lett 200; 293; 107-110.

27. Osei S.Y., Ahima R.S., Krupinski J. et al. Augmentation of renal vasoconstrictor response to norepinephrine and angiotensin II by leptin. Am J Hypertens 1999; 12:32A.

28. Lembo G., Vecchione C., Fratta L. et al. Leptin induces direct vasodilatation through distinct endothelial mechanisms. Diabetes 2000; 49:293-297.

29. Fruhbeck G., Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999; 48:903 -908.

30. Eikelis N., Schlaich M., Aggarwal A., Kaye D., Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003;41:1072-1079.

31. Correia M.L.G., Haynes W.G., Rahmouni K. et al. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002; 51:439-442.

32. Munzberg H., Flier J.S., Bjorbaek C. Region-specific leptin resistance within the hypothalamus of diet-induced-obese mice. Endocrinology 2004;145:4880-4889.

33. Shek E.W., Brands M.W., Hall J.E. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31:409-414.

34. Bouloumie A., Marumo T., Lafontan M. et al. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999; 13:1231 -1238.

35. Landsberg L. Hyperinsulinemia: possible role in obesity-induced hypertension. Hypertension 1992; 19:161-166.

36. Baskin D.G., Figlewicz D.P., Woods S.C. et al. Insulin in the brain. Ann Rev Physiol 1987; 49:335-347.

37. Vollenweider P., Tappy L., Randin D. et al. Differential effects of hyperinsulinemia and carbohydrate matabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 1993; 92:147-154.

38. Masuo K., Mikami H., Ogihara T., Tuck M.L. Sympathetic nerve hyperactivity preceded hyperinsulinemia and blood pressure elevation in a young, non-obese Japanese population. Am J Hypertens 1997;10:77-83.

39. Modan M., Halkin H., Almog S, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Inves. 1985;75:809-817.

40. Jamerson K.A., Julius S., Gudbrandson T. et al. Reflex sympathetic activation induces acute insulin reistance in the human forearm. Hypertension 1993; 21:618-623.

41. Watanabe K., Sekiya M., Takashi T. et al. Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. Hypertension 1999;17:1153-1160.

42. O’Hare J.A., Minaker K.L., Meneilly G.S., Rowe J.W., Pallotta J.A., Young J.B. Effect of insulin on plasma norepinephrine and 3,4-dihydroxy phenylalanine in obese men. Metabolism 1989;38:322-329.

43. Carretta R., Fabris B., Fischetti F., Costantini M., et al. Reduction of blood pressure in obese hyperinsulinemic hypertensive patients during somatostatin infusion. J Hypertens 1989; 7(Suppl 6):S196-197.

44. Tuck M.L. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 1992;19:167-177.

45. Grassi G., Seravalle G., Colombo M., Bola G., Cattaneo B.M., Cavagnini F., Manda G. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998;97:2037-2042.

46. Steffens A.B., Van der G.L., Godeke et al. Meal-induced increase in parasympathetic and sympathetic activity elicit simultaneous rises in plasma insulin and free fatty acids. Physiol Behav 1986;37:119-122.

47. Egan B.M., Schork N.J., Weder A.B. Regional homodynamic abnormalities in overweight men. Focus on alpha-adrenergic vascular responses. Am J Hyperetns 1989; 2:428-434.

48. Grekin R.J., Dumont C.J., Vollmer A.P. et al. Mechanisms of the pressor effects of hepatic portal venous fatty acid infusion. Am J Physiol 1997; 273.R324-R330.

49. Nielsen S., Guo Z., Johnson C.M., Hensrud D.D., Jensen M.D. Splanchnic lipolysis in human obesity. J Clin Invest. 2004;113:1582 -1588.

50. Scherrer U., Sartori C. Insulin as a vascular and sympathoexcitatory hormone. Circulation 1997;96:4104-4113.

51. Grassi G., Seravalle G., Dell'Oro R., et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36:538-542.

52. Bjomtrorp P., Holm G., Rosmond R., Folkow B. Hypertension and the metabolic syndrome: closely related central origin? Blood pressure 2000; 9:71-82

53. Brown M.R., Fisher L.A., Spiess J. et al. Corticoropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology 1982; 111:928-931.

54. Brown M.R., Fisher L.A. Corticoropin-releasing factor: effects on the autonomic nervous system and visceral systems. Fed Proc 1985; 44:243-248.

55. Randin D., Vollenweider P., Tappy L. et al. Suppression of alcohol-induced hypertension by dexamethazone N Eng J Med 1995; 332:1733-1737.

56. Scherrer U., Vollenweider P., Randin D. et al. Suppression of insulin-induced sympathetic activation and vasodilation by dexamethasone in humans. Circulation 1993; 88:388-394.

57. Grasi G., Seravalle G., Dell'Oro R. et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36:538-542.

58. Poykko S.M., Kellokoski E., Horkko S., Kauma H., Kesaniemi Y.A., Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003,52:2546 -2553.

59. Iwashima Y., Katsuya T., Ishikawa K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43:1318-1323.

60. Lin Y., Matsumura К., Fukuhara Μ., Kagiyama S., Fujii К., Iida M. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 2004;43:977-982.

61. Paquali R., Cantobelli S., Casimirri F., Boroluzzi L., Boschi S., Capelli M., Melchionda N., Barbara L: The role of opioid peptides in the development of hyperinsulinemia in obese women with abdominal fat distribution. Metabolism 1992;41:763-767.

62. McCubbin J.A., Survit R.S., Williams R.B., Nemeroff C.B., McNeilly M: Altered pituitary hormone response to naloxone in hypertension development. Hypertension 1989;14:636-644.

63. Young T., Palta M., Dempsey J., et al.The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328:1230-1235.

64. Partinen M. Ischaemic stroke, snoring and obstructive sleep apnea. J Sleep Res 1995;4:156-159.

65. He J., Kryger M.H. et al. Mortality and apnea index in obstructive sleep apnea. Chest 1988; 96:480-488.

66. Andreas S., Shulz R., Werner G.S. et al. Prevalence of obstructive sleep apnea among patients with coronary artery disease. Coronary Artery Dis 1996;7:541-545.

67. De Olazabal J.R., Miller M.J., Cook W.R. et al. Disordered breathing and hypoxia during sleep in coronary artery disease. Chest 1982;82:548-552.

68. Guilleminault C., Conolly S.J., Winkle R.A. et al. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. Am J Cardiol 1983;52:490-494.

69. Saito T., Yoshikawa T., Sakomoto Y. et al. Sleep apnea in patients with acute myocardial infarction. Crit. Care Med. - 1991. - V. 19. -P. 938-941.

70. Mooe T., Rabben T., Wiklund U. et al. Sleep-disordered breathing in men with coronary artery disease. Chest 1996,109:659 -653.

71. Wilcox I., McNamara S.G. et al. “Syndrome Z”: the interaction of sleep apnea, vascular risk factors and heart disease. Thorax 1998; 53(Suppl. 3):S5-S28.

72. Narkiewicz K., van de Borne P.J., Montano N., et al. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 1998;97:943-945.

73. Phillips B.G., Kato M., Narkiewicz К. et al. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea Am J Physiol 2000;279:H234-H237.

74. Phillips B.G., Somers V.K. Neural and humoral mechanisms mediating cardiovascular responses to obstructive sleep apnea. Respir Physiol 2000;119:181-187.

75. Fletcher E.С. Cardiovascular consequences of obstructive sleep apnea: experimental hypoxia and sympathetic activity. Sleep 2000,23 (Suppl 4):S127-131.

76. Salvador J., Marte J., Silva C. et al. The obstructive sleep apnea syndrome in obesity: a conspirator in the shadow. Rev Med Univ Neverra 2004:48:55-62.

77. Narkiewicz Κ., van de Borne P.J., Pesek C.A. et al. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea Circulation 1999:99: 1183-1189.

78. Coy T.V., Dimsdale J.E., Ancoli I.S. et al. Sleep apnea and sympathetic nervous system activity: a review. J Sleep Res 1996;5:42-50.

79. Elmasry A., Lindberg E., Berne C. et al. Sleep-disodered breathing and glucose metabolism in hypertensive men: a population-based study. J Intern Med 2000; 249:153-161.

Для цитирования:

Конради А.О. Ожирение, симпатическая гиперактивность и артериальная гипертензия -есть ли связь? Артериальная гипертензия. 2006;12(2):131-140.

For citation:

Conrady A.O. Obesity, sympathetic nervous system, and hypertension - are they connected? "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2006;12(2):131-140. (In Russ.)

Просмотров: 340

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)